News Quantified

ANIX – anixa biosciences, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Anixa Biosciences (ANIX) was upgraded by Wall Street Zen from "sell"

Anixa Biosciences (ANIX) was downgraded by Wall Street Zen from "hold

Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress [Yahoo! Finance]

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast [Yahoo! Finance]

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

0.0%

BEAT

3.1%

MISS

-0.3%

BEAT

Form 8-K Anixa Biosciences Inc For: Mar 10

Form 10-Q Anixa Biosciences Inc For: Jan 31

Form 8-K Anixa Biosciences Inc For: Feb 09

Form 4 Anixa Biosciences Inc For: Jan 28 Filed by: Baskies Arnold M

Form DEF 14A Anixa Biosciences Inc For: Jan 28

Top News Gainers

7/17 Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology 13.1%

12/30 ITUS Corporation (NYSE: ANIX) had its price target lowered by analysts at B. Riley from $11.25 to $8.00. They now have a "buy" rating on the stock. 11.8%

1/14 Form 4 Anixa Biosciences Inc For: Jan 14 Filed by: KUMAR AMIT 10.4%

11/26 Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study 7.3%

1/16 Form 4 Anixa Biosciences Inc For: Jan 15 Filed by: Titterton Lewis H jr 6.9%

10/15 Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts 5.7%

12/23 Anixa Biosciences to Present at Biotech Showcase 2020 5.5%

4/27 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.8%

1/21 Form 4 Anixa Biosciences Inc For: Jan 17 Filed by: Baskies Arnold M 4.8%

8/21 Form 8-K Anixa Biosciences Inc For: Aug 21 4.6%

Top News Decliners

3/9 Q1/2020 1/31/2020 EPS -0.130 ZacksConsensus -0.130 ActVsEst 0.000 - In-Line -18.5%

12/13 Anixa Biosciences Provides Update on CAR-T Program -15.1%

4/20 Anixa Bio up 30% premarket on plan to develop COVID-19 drugs [Seeking Alpha] -12.6%

1/1 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -8.5%

3/23 ITUS Corporation (NYSE: ANIX) is now covered by analysts at Aegis. They set a "buy" rating and a $8.50 price target on the stock. -6.1%

3/24 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%

7/18 Form 8-K Anixa Biosciences Inc For: Jul 12 -4.4%

6/11 Form S-3 Anixa Biosciences Inc -3.6%

1/10 Form 10-K/A Anixa Biosciences Inc For: Oct 31 -3.5%

4/20 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -3.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day